婦人科用医薬品の世界市場

◆英語タイトル:Gynecology Drugs Market (Therapeutics - Hormonal Therapy, Non-Hormonal Therapy; Indication - Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control); Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026
◆商品コード:TPM-C03042
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年1月
◆ページ数:213
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、婦人科用医薬品の世界市場について調べ、婦人科用医薬品の世界規模、市場動向、市場環境、治療別(ホルモン療法、非ホルモン療法)分析、適応症別(婦人科系がん、子宮内膜症、女性の不妊症、更年期障害、婦人科系感染症、多嚢胞性卵巣症候群、避妊)分析、流通経路別(院内薬局、小売薬局、オンライン薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・婦人科用医薬品の世界市場動向
・婦人科用医薬品の世界市場環境
・婦人科用医薬品の世界市場規模
・婦人科用医薬品の世界市場規模:治療別(ホルモン療法、非ホルモン療法)
・婦人科用医薬品の世界市場規模:適応症別(婦人科系がん、子宮内膜症、女性の不妊症、更年期障害、婦人科系感染症、多嚢胞性卵巣症候群、避妊)
・婦人科用医薬品の世界市場規模:流通経路別(院内薬局、小売薬局、オンライン薬局)
・婦人科用医薬品の世界市場:地域別市場規模・分析
・婦人科用医薬品の北米市場規模・予測
・婦人科用医薬品のアメリカ市場規模・予測
・婦人科用医薬品の中南米市場規模・予測
・婦人科用医薬品のヨーロッパ市場規模・予測
・婦人科用医薬品のアジア市場規模・予測
・婦人科用医薬品の日本市場規模・予測
・婦人科用医薬品の中国市場規模・予測
・婦人科用医薬品のインド市場規模・予測
・婦人科用医薬品の中東市場規模・予測
・婦人科用医薬品のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Global Gynecology Drugs market: Overview

This report analyzes the current and future scenario of the global gynecology drugs market. High incidence and prevalence of gynecology diseases and rise in patient awareness are major drivers of the global market.

The global gynecology drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on therapeutics, indication, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global gynecology drugs market.

Global Gynecology Drugs Market: Key Segments

The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rise in adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the global market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is estimated to expand at a significant CAGR during forecast period, owing to the ease of use of online pharmacies and a rise in the number of internet users. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Gynecology Drugs Market: Regional Outlook

In terms of region, the global gynecology drugs market has been segmented into five major regions and key countries/sub-regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global gynecology drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players in the global gynecology drugs market are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG.

The global gynecology drugs market has been segmented as given below:

Global Gynecology Drugs Market, by Therapeutics
Hormonal Therapy
Estrogen Therapy
Progestin Therapy
Combination Therapy
Thyroid Replacement Therapy
Parathyroid Hormone Therapy
Others
Non-hormonal Therapy
Anti-Infective Agents
Anti-neoplastic Agents
Anti-inflammatory Agents
Others
Global Gynecology Drugs Market, by Indication
Gynecology Cancers
Endometriosis
Female Infertility
Menopausal Disorder
Gynecology Infections
Polycystic Ovary Syndrome
Contraception (Birth Control)
Others
Global Gynecology Drugs Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Gynecology Drugs Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Gynecology Drugs Market: Market Snapshot

4. Market Overview
4.1. Global Gynecology Drugs Market: Product Overview
4.2. Global Gynecology Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gynecology Drugs Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis
4.6. Global Gynecology Drugs Market Outlook

5. Market Outlook
5.1. Regulatory Scenario
5.2. Disease Prevalence
5.3. Pipeline Analysis

6. Global Gynecology Drugs Market Analysis, by Therapeutics
6.1. Key Findings
6.2. Introduction
6.3. Global Gynecology Drugs Market Value Share, by Therapeutics
6.4. Global Gynecology Drugs Market Value Forecast, by Therapeutics
6.4.1. Hormonal Therapy
6.4.1.1. Estrogen Therapy
6.4.1.2. Progestin Therapy
6.4.1.3. Combination Therapy
6.4.1.4. Thyroid Replacement Therapy
6.4.1.5. Parathyroid Hormone Therapy
6.4.1.6. Others
6.4.2. Non-hormonal Therapy
6.4.2.1. Anti-Infective Agents
6.4.2.2. Anti-neoplastic Agents
6.4.2.3. Anti-inflammatory Agents
6.4.2.4. Others
6.5. Global Gynecology Drugs Market Analysis, by Therapeutics
6.6. Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics

7. Global Gynecology Drugs Market Analysis, by Indication
7.1. Key Findings
7.2. Introduction
7.3. Global Gynecology Drugs Market Value Share, by Indication
7.4. Global Gynecology Drugs Market Value Forecast, by Indication
7.4.1.1. Gynecology Cancers
7.4.1.2. Endometriosis
7.4.1.3. Female Infertility
7.4.1.4. Menopausal Disorder
7.4.1.5. Gynecology Infections
7.4.1.6. Polycystic Ovary Syndrome
7.4.1.7. Contraception (Birth Control)
7.4.1.8. Others
7.5. Global Gynecology Drugs Market Analysis, by Indication
7.6. Global Gynecology Drugs Market Attractiveness Analysis, by Indication

8. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Gynecology Drugs Market Value Share, by Distribution Channel
8.4. Global Gynecology Drugs Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.6. Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Gynecology Drugs Market Analysis, by Region
9.1. Global Gynecology Drugs Market Scenario, by Country
9.2. Global Gynecology Drugs Market Value Share, by Region
9.3. Global Gynecology Drugs Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Gynecology Drugs Market Attractiveness Analysis, by Region

10. North America Gynecology Drugs Market Analysis
10.1. Key Findings
10.2. North America Gynecology Drugs Market Overview
10.3. North America Gynecology Drugs Market Value Share, by Country
10.4. North America Gynecology Drugs Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Gynecology Drugs Market Value Share Analysis, by Therapeutics
10.6. North America Gynecology Drugs Market Forecast, by Therapeutics
10.6.1. Hormonal Therapy
10.6.1.1. Estrogen Therapy
10.6.1.2. Progestin Therapy
10.6.1.3. Combination Therapy
10.6.1.4. Thyroid Replacement Therapy
10.6.1.5. Parathyroid Hormone Therapy
10.6.1.6. Others
10.6.2. Non-hormonal Therapy
10.6.2.1. Anti-Infective Agents
10.6.2.2. Anti-neoplastic Agents
10.6.2.3. Anti-inflammatory Agents
10.6.2.4. Others
10.7. North America Gynecology Drugs Market Value Share Analysis, by Indication
10.8. North America Gynecology Drugs Market Forecast, by Indication
10.8.1. Gynecology Cancers
10.8.2. Endometriosis
10.8.3. Female Infertility
10.8.4. Menopausal Disorder
10.8.5. Gynecology Infections
10.8.6. Polycystic Ovary Syndrome
10.8.7. Contraception (Birth Control)
10.8.8. Others
10.9. North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
10.10. North America Gynecology Drugs Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.11. North America Gynecology Drugs Market Attractiveness Analysis

11. Europe Gynecology Drugs Market Analysis
11.1. Key Findings
11.2. Europe Gynecology Drugs Market Overview
11.3. Europe Gynecology Drugs Market Value Share, by Country/Sub-region
11.4. Europe Gynecology Drugs Market Forecast, by Country/Sub-region
11.4.1. UK
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics
11.6. Europe Gynecology Drugs Market Forecast, by Therapeutics
11.6.1. Hormonal Therapy
11.6.1.1. Estrogen Therapy
11.6.1.2. Progestin Therapy
11.6.1.3. Combination Therapy
11.6.1.4. Thyroid Replacement Therapy
11.6.1.5. Parathyroid Hormone Therapy
11.6.1.6. Others
11.6.2. Non-hormonal Therapy
11.6.2.1. Anti-Infective Agents
11.6.2.2. Anti-neoplastic Agents
11.6.2.3. Anti-inflammatory Agents
11.6.2.4. Others
11.7. Europe Gynecology Drugs Market Value Share Analysis, by Indication
11.8. Europe Gynecology Drugs Market Forecast, by Indication
11.8.1. Gynecology Cancers
11.8.2. Endometriosis
11.8.3. Female Infertility
11.8.4. Menopausal Disorder
11.8.5. Gynecology Infections
11.8.6. Polycystic Ovary Syndrome
11.8.7. Contraception (Birth Control)
11.8.8. Others
11.9. Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel
11.10. Europe Gynecology Drugs Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Europe Gynecology Drugs Market Attractiveness Analysis

12. Asia Pacific Gynecology Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Gynecology Drugs Market Overview
12.3. Asia Pacific Gynecology Drugs Market Value Share, by Country/Sub-region
12.4. Asia Pacific Gynecology Drugs Market Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics
12.6. Asia Pacific Gynecology Drugs Market Forecast, by Therapeutics
12.6.1. Hormonal Therapy
12.6.1.1. Estrogen Therapy
12.6.1.2. Progestin Therapy
12.6.1.3. Combination Therapy
12.6.1.4. Thyroid Replacement Therapy
12.6.1.5. Parathyroid Hormone Therapy
12.6.1.6. Others
12.6.2. Non-hormonal Therapy
12.6.2.1. Anti-Infective Agents
12.6.2.2. Anti-neoplastic Agents
12.6.2.3. Anti-inflammatory Agents
12.6.2.4. Others
12.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication
12.8. Asia Pacific Gynecology Drugs Market Forecast, by Indication
12.8.1. Gynecology Cancers
12.8.2. Endometriosis
12.8.3. Female Infertility
12.8.4. Menopausal Disorder
12.8.5. Gynecology Infections
12.8.6. Polycystic Ovary Syndrome
12.8.7. Contraception (Birth Control)
12.8.8. Others
12.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Gynecology Drugs Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Asia Pacific Gynecology Drugs Market Attractiveness Analysis

13. Latin America Gynecology Drugs Market Analysis
13.1. Key Findings
13.2. Latin America Gynecology Drugs Market Overview
13.3. Latin America Gynecology Drugs Market Value Share, by Country/Sub-region
13.4. Latin America Gynecology Drugs Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics
13.6. Latin America Gynecology Drugs Market Forecast, by Therapeutics
13.6.1. Hormonal Therapy
13.6.1.1. Estrogen Therapy
13.6.1.2. Progestin Therapy
13.6.1.3. Combination Therapy
13.6.1.4. Thyroid Replacement Therapy
13.6.1.5. Parathyroid Hormone Therapy
13.6.1.6. Others
13.6.2. Non-hormonal Therapy
13.6.2.1. Anti-Infective Agents
13.6.2.2. Anti-neoplastic Agents
13.6.2.3. Anti-inflammatory Agents
13.6.2.4. Others
13.7. Latin America Gynecology Drugs Market Value Share Analysis, by Indication
13.8. Latin America Gynecology Drugs Market Forecast, by Indication
13.8.1. Gynecology Cancers
13.8.2. Endometriosis
13.8.3. Female Infertility
13.8.4. Menopausal Disorder
13.8.5. Gynecology Infections
13.8.6. Polycystic Ovary Syndrome
13.8.7. Contraception (Birth Control)
13.8.8. Others
13.9. Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
13.10. Latin America Gynecology Drugs Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Latin America Gynecology Drugs Market Attractiveness Analysis

14. Middle East & Africa Gynecology Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Gynecology Drugs Market Overview
14.3. Middle East & Africa Gynecology Drugs Market Value Share, by Country/Sub-region
14.4. Middle East & Africa Gynecology Drugs Market Forecast, by Country/Sub-region
14.4.1. GCC
14.4.2. South Africa
14.4.3. Rest of MEA
14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics
14.6. Middle East & Africa Gynecology Drugs Market Forecast, by Therapeutics
14.6.1. Hormonal Therapy
14.6.1.1. Estrogen Therapy
14.6.1.2. Progestin Therapy
14.6.1.3. Combination Therapy
14.6.1.4. Thyroid Replacement Therapy
14.6.1.5. Parathyroid Hormone Therapy
14.6.1.6. Others
14.6.2. Non-hormonal Therapy
14.6.2.1. Anti-Infective Agents
14.6.2.2. Anti-neoplastic Agents
14.6.2.3. Anti-inflammatory Agents
14.6.2.4. Others
14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication
14.8. Middle East & Africa Gynecology Drugs Market Forecast, by Indication
14.8.1. Gynecology Cancers
14.8.2. Endometriosis
14.8.3. Female Infertility
14.8.4. Menopausal Disorder
14.8.5. Gynecology Infections
14.8.6. Polycystic Ovary Syndrome
14.8.7. Contraception (Birth Control)
14.8.8. Others
14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis

15. Competition Landscape
15.1. Gynecology Drugs Market Share Analysis, by Company, 2017
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. Allergan plc.
15.3.1.1. Company Details
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Amgen Inc.
15.3.2.1. Company Details
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Bayer AG
15.3.3.1. Company Details
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Details
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Pfizer Inc.
15.3.5.1. Company Details
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Eli Lilly Company
15.3.6.1. Company Details
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Details
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. AstraZeneca
15.3.8.1. Company Details
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis

List of Tables

Table 01: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 02: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 03: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 04: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 05: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 07: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2026
Table 08: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 09: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 10: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 11: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 12: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 14: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 15: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 16: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 17: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 18: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 19: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 20: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 21: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 22: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 23: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 24: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 25: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 26: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 27: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 28: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 29: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 30: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 31: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 32: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 33: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 34: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 35: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 36: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Gynecology Drugs Market Revenue Projection (US$ Mn), 2016–2026
Figure 02: Global Gynecology Drugs Market Value Share, by Therapeutics, 2018
Figure 03: Global Gynecology Drugs Market Value Share, by Indication, 2018
Figure 04: Global Gynecology Drugs Market Value Share, by Region, 2018
Figure 05: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018
Figure 06: Global Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 07: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hormonal Therapy, 2016–2026
Figure 08: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Non-Hormonal Therapy, 2016–2026
Figure 09: Global Gynecology Drugs Market Attractiveness, by Therapeutics, 2018–2026
Figure 10: Global Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 11: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Cancers, 2016–2026
Figure 12: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Endometriosis, 2016–2026
Figure 13: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Female Infertility, 2016–2026
Figure 14: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Menopausal Disorder, 2016–2026
Figure 15: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Infections, 2016–2026
Figure 16: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Polycystic Ovary Syndrome, 2016–2026
Figure 17: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Contraception (Birth Control), 2016–2026
Figure 18: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 19: Global Gynecology Drugs Market Attractiveness, by Indication
Figure 20: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 21: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 22: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 23: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 24: Global Gynecology Drugs Market Attractiveness, by Distribution Channel
Figure 25: Global Gynecology Drugs Market Value Share, by Region, 2018 and 2026
Figure 26: Global Gynecology Drugs Market Attractiveness, by Region, 2018–2026
Figure 27: North America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 28: North America Gynecology Drugs Market Attractiveness Analysis, by Country
Figure 29: North America Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 30: North America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 31: North America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 32: North America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 33: North America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 34: North America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 35: North America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 36: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 37: Europe Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 38: Europe Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 39: Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 40: Europe Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 41: Europe Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 42: Europe Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 43: Europe Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 44: Europe Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 46: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 47: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 48: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 49: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 50: Asia Pacific Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 51: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 52: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 53: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 54: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 55: Latin America Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 56: Latin America Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 57: Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 58: Latin America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 59: Latin America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 60: Latin America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 61: Latin America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 62: Latin America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 64: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 65: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 66: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 67: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 68: Middle East & Africa Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 69: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 70: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 71: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 72: Global Gynecology Drugs Market Share Analysis, by Company, 2017 (Estimated)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[婦人科用医薬品の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆